Ignite Creation Date:
2024-05-06 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05722912
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2023-02-10
First Post:
2022-10-04
Brief Title:
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Study Overview
Official Title:
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None